Corona Remedies has announced the expansion of its Bhayla manufacturing facility by 400 million units, enhancing its capacity to produce tablets and capsules.

The expansion, which began on 22 December, 2025, is funded through internal accruals and is aimed at addressing the growing market demand while boosting the company's in-house production capabilities. With this expansion, the Bhayla facility's installed capacity will increase significantly, reaching a total of 1.25 billion units. As of March 2025, the facility had an installed capacity of 852.80 million units, with a utilisation rate of 93.58 percent.

Commenting on the expansion, a company spokesperson stated that the move is part of their strategy to meet the increasing demand in the pharmaceutical market and to strengthen their production capabilities for future growth.